Akero Therapeutics Inc (AKRO)
19.66
-0.05
(-0.25%)
USD |
NASDAQ |
May 03, 16:00
19.64
-0.02
(-0.10%)
After-Hours: 20:00
Akero Therapeutics Research and Development Expense (Quarterly): 53.39M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 53.39M |
| September 30, 2023 | 38.63M |
| June 30, 2023 | 27.98M |
| March 31, 2023 | 21.79M |
| December 31, 2022 | 18.32M |
| September 30, 2022 | 25.09M |
| June 30, 2022 | 21.36M |
| March 31, 2022 | 20.51M |
| December 31, 2021 | 27.71M |
| September 30, 2021 | 19.47M |
| June 30, 2021 | 23.98M |
| March 31, 2021 | 10.60M |
| Date | Value |
|---|---|
| December 31, 2020 | 25.71M |
| September 30, 2020 | 17.38M |
| June 30, 2020 | 13.04M |
| March 31, 2020 | 8.791M |
| December 31, 2019 | 13.14M |
| September 30, 2019 | 13.88M |
| June 30, 2019 | 5.96M |
| March 31, 2019 | 4.063M |
| December 31, 2018 | 1.983M |
| September 30, 2018 | 1.253M |
| June 30, 2018 | 8.42M |
| March 31, 2018 | 0.226M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.96M
Minimum
Jun 2019
53.39M
Maximum
Dec 2023
21.41M
Average
20.51M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| 89bio Inc | 33.59M |
| Viking Therapeutics Inc | 24.10M |
| Eli Lilly and Co | 2.523B |
| Ionis Pharmaceuticals Inc | 256.56M |